Drug-induced olfactory and gustatory dysfunction: Analysis of FDA adverse events reporting system.

OBJECTIVES: With the COVID-19 pandemic, there is growing interest and research in olfactory and gustatory dysfunction (OGD). Drug-induced dysfunction is an often overlooked etiology. While several medications include smell or taste disturbance as a side effect, there are no publications describing which medications are most frequently implicated. We aim to describe the patterns of these adverse drug reactions (ADRs) using the FDA Adverse Events Reporting System (FAERS). METHODS: The FAERS database was queried from 2011 to 2021 for terms describing ADRs related to OGD. Terms included anosmia, hyposmia, olfactory test abnormal, olfactory nerve disorder, hallucination olfactory, parosmia, ageusia, hypogeusia, dysgeusia, and taste disorder. We identified the top reported medications associated with general smell dysfunction, general taste dysfunction, reduced smell, and altered smell. RESULTS: From 2011 to 2021, 16,091 ADRs were reported with OGD, of which13,641 (84.8%) and 2,450 (15.2%) were associated with gustatory and olfactory reactions, respectively. Zinc products (370 reports) and fluticasone propionate (214) were most commonly associated with olfactory dysfunction, specifically reduced olfaction. Varenicline (24) and fluticasone propionate (23) were most commonly associated with altered smell. Lenalidomide (490) and sunitinib (468) were most commonly associated with gustatory dysfunction. Antineoplastic and immunomodulating medications accounted for 21.6% and 36.3% of olfactory and gustatory ADRs, respectively. Among this category, immunoglobulin drugs were the most commonly associated with OGD ADRs. CONCLUSION: Gustatory dysfunction is more commonly reported ADR compared with olfactory dysfunction. Immunologic/rheumatologic medications are the leading culprit of reported OGD. With increasing numbers of patients presenting to otolaryngologists for OGD, it is important to consider drug-induced etiology. LEVEL OF EVIDENCE: III.

Has Smartphone Use Influenced Loneliness during the COVID-19 Pandemic in Japan?

The influence of smartphone use on increased risk of feeling lonely has been recognized as a global public health concern. However, it is unclear whether this influence has changed during the ongoing COVID-19 pandemic, during which smartphones have become a particularly important means of communication due to health safety measures restricting personal interactions. We used Hiroshima University's online survey data collected from 18-28 February 2022, to assess the impact of smartphone use on loneliness in Japan. The final sample included 2630 participants aged over 20 years, with loneliness measured using the UCLA scale and smartphone use calculated as the duration of usage in minutes/day. Weighted logit regression analysis was used to examine the association between smartphone use and loneliness, with other demographic, socioeconomic, and psychological characteristics as explanatory variables. Contrary to conventional evidence, our findings show that smartphone use mitigated the risk of loneliness during the pandemic. This was especially true among females under 65 years old. We found that age, subjective health status, future anxiety, and depression impacted this relationship. The findings of this study can help guide policymaking by showing the importance of providing adequate digital platforms to manage loneliness and mental health during times of isolation.